NanoViricides Develops Promising Measles Antiviral

NanoViricides, Inc., a clinical stage company, announced a breakthrough in Measles treatment. Their broad-spectrum antiviral candidate, NV-387, showed strong effectiveness in animal studies. Using a humanized mouse model, NV-387 increased survival times significantly, up to 17 days from 7.4 days without treatment.

NV-387 is designed to target viruses by mimicking cell receptors, effectively neutralizing them. This drug leverages similarities with other paramyxoviruses, showcasing its potential as a pioneering treatment for Measles. The ongoing decline in vaccination rates highlights the urgent need for such a treatment.

The company is advancing NV-387 towards Phase II trials, also aiming to tackle other viral infections. As vaccine efficacy faces challenges, NV-387 offers a promising solution amid rising Measles cases.